Efficacy and safety of recombinant activated factor vii in the management of hemorrhagic shock due to trauma

The CONTROL Study Group, Department of Surgery, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, United States; Department of Surgery, Johannesburg Hospital, University of the Witwatersrand, Johannesburg, South Africa; Department of Anesthesiology, University of Maryland School of Medicine and R. Adams Cowley Shock Trauma Center, Baltimore; Department of Internal Medicine, Vanderbilt School of Medicine, Nashville; Department of Surgery, University of Tennessee Health Science Center, Memphis; Department of Surgery, University of Texas Health Science Center, Houston, United States; Department of Emergency Surgery, Meilahti Hospital, University of Helsinki, Helsinki, Finland; Intensive Care Unit, Liverpool Hospital, University of New South Wales, Sydney, Australia; Department of Intensive Care, Erasme University Hospital (Universit√ö Libre de Bruxelles), Brussels, Belgium;Trauma & Critical Care Research, Novo Nordisk Inc., Princeton, United States; Global Development, Novo Nordisk A/S, Bagsvaerd, Denmark; Department of Trauma and Orthopedic Surgery, University of Witten/Herdecke Cologne Merheim Medical Center, Cologne, Germany

ISTH Congress. 2009;: Abstract No. OC-TH-069.
Study details